MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced it has entered into an exclusive agreement with Summit Products Group ("Summit") to distribute three innovative, 510(k) cleared products that complement the Company's leading Surgical & Wound product portfolio: Hydrelix, NovaForm®, and G4Derm® Plus.

About the products:

  • Hydrelix Collagen Matrix is a sterile, Type 1 collagen powder, comprised of soluble modified bovine collagen. The product is formulated from hydrolyzed and modified collagens in powdered form, bypassing the need for further enzymatic degradation by the body. This allows the bioactive components of collagen to be readily available at the wound site, facilitating a more direct and efficient therapeutic effect.
  • NovaForm Wound Matrix is a proprietary bioglass and collagen-based wound dressing intended for use in the management of partial and full-thickness wounds, such as pressure ulcers, venous ulcers, diabetic ulcers and surgical wounds. The highly conformable, bioengineered matrix is designed to protect the wound, while maintaining a moist environment that supports the body's natural healing process.
  • G4Derm Plus is a flowable peptide matrix engineered for rapid, protected wound closure. The product forms a 3D scaffold that mimics the human extracellular matrix (ECM) and serves as an antibacterial barrier that protects the wound. The biomimetic matrix is uniquely positioned to simultaneously spur tissue regrowth and control bioburden.

"We are excited to announce this distribution agreement with Summit to meaningfully expand our product offering with Hydrelix, NovaForm and G4Derm Plus. These are innovative xenograft and synthetic products that strengthen our ability to serve the Surgical & Wound markets," stated Kim Moller, MIMEDX Chief Commercial Officer. "As the landscape of this market continues to evolve, MIMEDX remains a leader in supporting customers and their patients with proven products."

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

About Summit Products Group
Summit Products Group is a specialized healthcare company dedicated to advancing surgical and regenerative solutions. With a mission to innovate, cultivate and elevate market-leading solutions, Summit Products Group identifies breakthrough products, guides them through regulatory pathways and delivers them to providers who demand clinical excellence. Through strategic partnerships, integrated logistics, and a deep understanding of FDA compliance, Summit Products Group brings clarity and confidence to the commercialization of novel technologies. On the web: www.summitproductsgroup.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

MDXG
The Conversation (0)
MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 21 st Annual Institutional Investor Conference Wednesday, May 29, 2024 Renaissance Minneapolis Hotel, The Depot... Keep Reading...
MIMEDX Announces First Quarter 2024 Operating and Financial Results

MIMEDX Announces First Quarter 2024 Operating and Financial Results

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024 , at 4:30 PM ET MiMedx Group, Inc. (Nasdaq: MDXG)... Keep Reading...
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...
Satellos Bioscience Inc.

Satellos Bioscience Inc.

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this... Keep Reading...
Vaxcyte Inc.

Vaxcyte Inc.

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. Keep Reading...

Interactive Chart

Latest Press Releases

Related News